An observational study in Fabry Disease, sponsored by Chiesi Italia. Completed at 7 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-28.
Sponsored by Chiesi Italia (part of Chiesi Farmaceutici S.p.A.) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Fabry Disease by Chiesi Farmaceutici S.p.A. — 5 open to participants now, 5 under way, 2 of them phase 3. Fabry Disease · Chiesi Farmaceutici S.p.A..
Among the 10 studies in Fabry Disease by Chiesi Farmaceutici S.p.A., this one is the only one that started in 2021, is one of 5 observational ones, and was the 4th registered.
244 studies on the registry are indexed under Fabry Disease; 54 are open to participants now.
Browse Fabry Disease studies →5 of the 10 studies in Fabry Disease by Chiesi Farmaceutici S.p.A. are open now, in 10 countries. Recruiting first, the newest first:
Chiesi Italia · Sites in Italy
Ages 18+
Chiesi Farmaceutici S.p.A. · Sites in United States, Austria, France and 3 more countries
Ages 2–17
Chiesi Farmaceutici S.p.A. · Sites in United States, Germany, Italy and 2 more countries
Women only
Chiesi Farmaceutici S.p.A. · Sites in United States, Slovenia, United Kingdom
Ages 18+
Chiesi Farmaceutici S.p.A. · Sites in Japan
Ages 13–70
By country, each count listing its studies:
Of the 44 Fabry Disease studies recruiting now, 31 (70%) set no upper age limit and 11 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 4
First in 2018; this study’s year is marked. 1 started in 2021.
This study's enrollment of 200 is above the median of 100 across 122 observational studies indexed under Fabry Disease.
Median enrollment 26 across the 4 interventional studies, 75 across the 5 observational. Of the 4 that completed or were terminated, 1 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Chiesi Italia, one of the names counted as Chiesi Farmaceutici S.p.A.. Under that name alone:
Chiesi Italia is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
1 of the studies in Fabry Disease by Chiesi Farmaceutici S.p.A. that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05710692Phase 3Chiesi Farmaceutici S.p.A.Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry Disease | 2027-10 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Fabry Disease by Chiesi Farmaceutici S.p.A., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
GROUND study is an Italian, multicenter retrospective longitudinal cohort study with a cross-sectional phase with the aim to quantify the severe clinical burden in terms of severe and fatal outcomes and extension of clinical impairment in the Italian Fabry Disease patients' population
Patients with a confirmed FD diagnosis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: FD patients
Patients with Fabry disease diagnosis
Occurrence of severe and fatal clinical outcomes
Occurrence of severe and fatal clinical outcomes derived by event-free survival from birth to last follow-up or cross-sectional visit;
Time frame: Baseline
Comprehensive burden
Comprehensive burden intended as a measure of extension of clinical impairment assessed by median Mainz Severity Score Index (MSSI) at last follow-up or cross-sectional visit.
Time frame: Baseline
Percentage of patients with disease progression
Percentage of patients with disease progression measured by FAbry STabilization indEX and defined as a change \>20% from the first available FASTEX score to the last follow-up and in the last 2 years until the last follow-up and 2 years before the last follow-up or cross-sectional visit (or when available within 3-1 years before last follow-up)
Time frame: From the first available FASTEX score to baseline
Percentage of patients with disease activity
Percentage of patients with disease activity assessed by the occurrence rate of clinically significant events from diagnosis to last follow-up or cross-sectional visit.
Time frame: Baseline
Brief pain inventory score
Uses simple numeric rating scales from 0 (no pain) to 10 (severe pain)
Time frame: Baseline
Pittsburgh Sleep Quality index
Seven component scores are derived, each scored 0 (no difficulty) to 3 (severe difficulty). The component scores are summed to produce a global score (range 0 to 21). Higher scores indicate worse sleep quality.
Time frame: Baseline
Hamilton depression scale
It contains 17 items. A score of 0-7 is considered to be normal while a score of 20 or higher (indicating at least moderate severity)
Time frame: Baseline
HAQ-disability index
There are 8 sections: dressing, arising, eating, walking, hygiene, reach, grip, and activities. There are 2 or 3 questions for each section. Scoring within each section is from 0 (without any difficulty) to 3 (unable to do).The 8 scores of the 8 sections are summed and divided by 8.
Time frame: Baseline
SF-36
Covers eight health domains: physical functioning (10 items), bodily pain (2 items), role limitations due to physical health problems (4 items), role limitations due to personal or emotional problems (4 items), emotional well-being (5 items), social functioning (2 items), energy/fatigue (4 items), and general health perceptions (5 items). Scores for each domain range from 0 to 100, with a higher score defining a more favorable health state.
Time frame: Baseline
Time from first manifestation to diagnosis
Time from first manifestation to diagnosis
Time frame: Baseline
Patients prescribed to different treatments
Percentage of patients prescribed to different treatment among naïve and switchers groups; determinants of untreated, treated discontinue, treated persisting status.
Time frame: Baseline
Plan to share: No
Ran from Jun 2021 to primary completion in Jun 2022, 12 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.